GT19630
Based on 1 Customer Validation
GT19630 is an orally active c-Myc PROTAC targeted degrader based on the cereblon E3 ubiquitin ligase, with an IC50 of 1.5 nM against human c-Myc. GT19630 mediates the degradation of MYC, GSPT1, GSPT2, CK1 alpha, N-Myc, B7-H3 and XIAP, and disrupts the MYC-GSPT1 synergistic regulatory feedback loop. GT19630 inhibits cell proliferation, blocks S-phase progression of the cell cycle, promotes cell apoptosis, reduces cell migration capacity, induces integrated stress response, and blocks oxidative phosphorylation by inhibiting the TCA cycle. GT19630 can be used in the research of Myc-driven hematological cancers, small cell lung cancer, breast cancer, TP53-mutant cancers, and venetoclax-resistant cancers.
(Pink: c-Myc ligand (HY-168685); Blue: Cereblon ligand (HY-W093472); Black: linker (HY-W015808)).
For research use only. We do not sell to patients.
- Purity : 98.85%
- CAS No.: 2883535-99-5
- Formula: C35H30N6O5
- Molecular Weight:614.65
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
|
c-Myc 1.5 nM (IC50) |
eRF3a/GSPT1 |
eRF3b/GSPT2 |
XIAP |
In Vitro
GT19630 selectively degrades c-Myc protein in HL60 AML cells with an IC50 of 1.5 nM, which is ~35-fold more potent than its activity in TF-1 erythroid progenitor cells (IC50 = 52.5 nM)[1].
GT19630 potently inhibits HL60 AML cell proliferation with an IC50 of 0.33 nM, demonstrating >100-fold selectivity over normal myeloid bone marrow colony-forming cells (IC50 = 40.2 nM) and ~79-fold selectivity over GM-CSF-stimulated TF-1 erythroid progenitor cells (IC50 = 26.2 nM)[1].
GT19630 (0.75-3 nM; 4-48 h) potently degrades MYC in BT549 and CAMA1 breast cancer cell lines, with degradation initiating at 0.75 nM (BT549) or 1.5 nM (CAMA1) by 48 h, and complete degradation achieved with 3 nM by 24 h[2].
GT19630 (0-100 nM; 5 days) inhibits proliferation of 14 diverse human breast cancer cell lines with IC50 values ranging from 1 to 100 nM, and exhibits consistent activity across major breast cancer molecular subtypes[2].
GT19630 (0.75-3 nM; 48 h) downregulates XIAP protein expression in BT549, CAMA1, and MDA-MB-468 breast cancer cell lines following 48 h treatment with 0.75, 1.5, or 3 nM[2].
GT19630 potently inhibits the proliferation of HL-60 acute myeloid leukemia cells with an IC50 of 0.33 nM[3].
GT19630 potently degrades c-Myc protein in HL-60 acute myeloid leukemia cells with an IC50 of 1.5 nM, and this degradation is dependent on proteasome activity[5].
GT19630 (salt form GT19715) potently inhibits HL-60 acute myeloid leukemia cell viability with an IC50 of 1.8 nM[5].
GT19630 selectively degrades GSPT1/GSPT2 (IC90 <1 nM) and CK1α (IC90 <10 nM) but does not degrade IKZF1/Ikaros in HL60 AML cells[1].
GT19630 (100 µM down to serial 3-fold dilutions; 195 min total) binds to human CRBN with high affinity, exhibiting an IC50 of 26.9 nM in an HTRF assay[4].
GT19630 (10 nM; 8 h) induces proteasome-dependent, sustained degradation of both MYC and GSPT1 proteins in HL-60 AML cells at low nanomolar concentrations[4].
GT19630 (variable concentrations; 24 h) induces significant stop-codon readthrough of MYC mRNA in HL-60 and HEK293T cells expressing a MYC-TGA-stop-EGFP reporter[4].
GT19630 (1-5nM; 24 h) induces the integrated stress response in HL-60 GTS AML cells by upregulating ATF4 and ATF3 and activating stress-related gene pathways[4].
GT19630 (5 nM; 12 h) potently inhibits oxidative phosphorylation and glycolysis in HL-60 GTS AML cells, reducing OCR, ECAR, and ATP-linked respiration[4].
GT19630 (5 nM; 12 h) disrupts the TCA cycle in HL-60 GTS AML cells by reducing glutamine metabolism and citrate flux, leading to accumulation of glycolysis intermediates[4].
GT19630 (5 nM; 12 h) decelerates TCA cycle flux in HL-60 GTS AML cells at the stages of glutamate synthesis and citrate synthesis, impairing mitochondrial respiration[4].
GT19630 (variable concentrations; 48 h) induces potent, TP53-agnostic anti-proliferative and apoptotic effects in most blood cancer and SCLC cell lines (IC50 <100 nM), with a therapeutic window relative to normal hematopoietic progenitors; efficacy is dependent on MYC degradation, with resistance in cells carrying a MYCp.T58I mutation[4].
GT19630 (64 nM; 72 h) induces greater cell death in AML LSPCs than normal NBM HSPCs, with TP53-agnostic activity, and reduces MYC protein levels more profoundly in AML LSPCs than normal HSPCs[4].
Biotinylated GT19630 binds directly to c-Myc protein in a cell-free in vitro affinity purification assay[5].
GT19630 (3-12 nM; 48 h) induces S phase cell cycle arrest in BT549, T47D, and MDA-MB-468 breast cancer cell lines following 48 h treatment with 3, 6, or 12 nM[2].
GT19630 (3.1-10000 nM; 48 h) induces apoptosis in T47D, CAMA1, BT549, MDA-MB-468, HCC70, and SKBR3 breast cancer cell lines after 48 h, with greater activity in cell lines with lower proliferation IC50 values[2].
GT19630 (0.75-3 nM) degrades the negative immune checkpoint protein B7-H3 in BT549, CAMA1, and MDA-MB-468 breast cancer cell lines, with concentration-dependent reduction in protein levels and no effect on mRNA expression[2].
GT19630 (3 nM; 24 h pre-treatment, 10-16 h migration) potently inhibits migration of BT549, CAMA1, and MDA-MB-468 breast cancer cell lines following 24 h pre-treatment with 3 nM, with the effect independent of apoptosis induction[2].
GT19630 (low nanomolar concentrations) exerts multifunctional antitumor effects in breast cancer cell lines, including inhibition of proliferation, induction of apoptosis, suppression of migration, degradation of B7-H3, activation of the integrated stress response, and disruption of oxidative phosphorylation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BT549, CAMA1 breast cancer cell lines
-
Concentration:0.75-3 nM (48 h incubation); 3 nM (4, 8, 24 h incubation)
-
Incubation Time:48 h (0.75, 1.5, 3 nM); 4, 8, 24 h (3 nM)
-
Result:Induced concentration-dependent MYC degradation, with degradation beginning at 0.75 nM in BT549 cells and at 1.5 nM in CAMA1 cells after 48 h.
Began MYC degradation as early as 8 h in both cell lines with 3 nM treatment, with no visible MYC bands detected by 24 h.
-
Cell Line:14 human breast cancer cell lines (luminal, HER2-positive, triple-negative subtypes)
-
Concentration:0-100 nM
-
Incubation Time:5 days
-
Result:Inhibited cell proliferation across all 14 breast cancer cell lines, with IC50 values ranging from 1 to 100 nM.
Exhibited similar anti-proliferative activity across luminal, HER2-positive, and triple-negative breast cancer subtypes.
-
Cell Line:BT549, T47D, MDA-MB-468 breast cancer cell lines
-
Concentration:3-12 nM
-
Incubation Time:48 h
-
Result:Resulted in accumulation of cells in the S phase of the cell cycle in all three cell lines.
Decreased the proportion of cells in the G1/G0 and G2/M phases in all three cell lines tested.
-
Cell Line:T47D, CAMA1, BT549, MDA-MB-468, HCC70, SKBR3 breast cancer cell lines
-
Concentration:3.1-12.5 nM (T47D, CAMA1, BT549, MDA-MB-468); 25-100 nM (HCC70); 2500-10000 nM (SKBR3)
-
Incubation Time:48 h
-
Result:Induced apoptosis in all six cell lines tested, with the extent of apoptosis dependent on cell line, concentration, and incubation time.
Showed greater susceptibility to apoptosis in cell lines with lower proliferation IC50 values (≤5 nM: T47D, CAMA1, BT549, MDA-MB-468), while cell lines with higher IC50 values (>40 nM: HCC70, SKBR3) were more resistant.
-
Cell Line:BT549, CAMA1, MDA-MB-468 breast cancer cell lines
-
Concentration:0.75-3 nM
-
Incubation Time:48 h
-
Result:Decreased XIAP protein expression in all three cell lines in a concentration-dependent manner.
Showed no consistent effect on XIAP mRNA expression across the cell lines.
-
Cell Line:BT549, CAMA1, MDA-MB-468 breast cancer cell lines
-
Concentration:0.75-3 nM (Western blot/ELISA); 3 nM (preliminary array screening)
-
Incubation Time:48 h (preliminary array screening)
-
Result:Decreased B7-H3 protein expression in all three cell lines in a concentration-dependent manner, as measured by both Western blot and ELISA.
Did not affect B7-H3 mRNA expression.
-
Cell Line:BT549, CAMA1, MDA-MB-468 breast cancer cell lines
-
Concentration:3 nM
-
Incubation Time:24 h pre-treatment; 10-16 h migration incubation
-
Result:Significantly reduced cell migration in all three cell lines tested.
Showed the decreased migration was not due to apoptosis, as no significant apoptosis was observed over the migration assay time course.
-
Cell Line:HL-60 AML cells (MYC-amplified)
-
Concentration:10 nM (with 50 nM MLN9708); low nanomolar concentrations (dose-dependent)
-
Incubation Time:8 h (with MLN9708); variable times (time-dependent); sustained up to 48 h post-washout
-
Result:Profoundly reduced MYC protein levels, with this reduction completely rescued by co-treatment with proteasome inhibitors.
Reduced MYC in a dose- and time-dependent manner at low nanomolar concentrations, with reduced MYC levels sustained up to 48 hours after washout.
Degraded GSPT1 protein, unlike the selective GSPT1 degrader CC-90009 which did not affect MYC levels.
-
Cell Line:HL-60 GT19630-sensitive (GTS) AML cells
-
Concentration:1 nM; 2 nM; 5nM (western blotting); 5 nM (RNA-seq)
-
Incubation Time:24 h (western blotting); 12 h (RNA-seq)
-
Result:Upregulated ATF4 and ATF3 protein levels.
Led to significant upregulation of ISR, stress response, and endoplasmic reticulum stress pathways as revealed by RNA-seq and GSEA.
-
Cell Line:diverse cancer cell lines (blood cancers, SCLCs, TNBCs, gliomas), normal erythroid or myeloid progenitors
-
Concentration:variable concentrations
-
Incubation Time:48 h
-
Result:Inhibited proliferation of most blood cancer and SCLC cell lines with IC50 values below 100 nM.
Induced apoptosis with IC50 values ≤10 nM in most cell lines.
Showed higher IC50 values (43-44 nM) in normal erythroid or myeloid progenitors compared to cancer cell lines.
Exhibited TP53-agnostic efficacy in myeloid and lymphoid cell lines, except Raji Burkitt’s lymphoma cells (harboring a MYC p.T58I mutation) which were resistant.
Induced significantly greater apoptosis in MYC-overexpressing OCI-AML3 cells compared to control cells.
In Vivo
GT19630 (0.1-1 mg/kg; i.p.; twice daily; i.p.; once daily (1 mg/kg)) significantly reduces HL-60 tumor volumes and MYC protein levels in BALB/c nude mice[4].
GT19630 (0.3-3 mg/kg; i.p.; twice daily) significantly reduces MM.1S tumor volumes in NOD/SCID mice[4].
GT19870 (3-12 mg/kg; p.o.; once daily) significantly reduces NCI H526 tumor volumes and MYC protein levels in BALB/c nude mice[4].
GT19870 (3-12 mg/kg; p.o.; once daily) significantly reduces 22RV1 tumor volumes and MYC protein levels in BALB/c nude mice[4].
GT19630 (3 mg/kg; i.p.; once daily) eradicates relapsed AML PDX cells in NOD/SCID mice[4].
GT19630 (3 mg/kg; i.p.; three times weekly; 2 weeks on/1 week off cycles) reduces leukemia burden and prolongs survival by >300% in venetoclax-resistant MV4;11 AML in NSG mice[4].
GT19630 (0.3 mg/kg; twice daily) degrades c-Myc and GSPT1 and inhibits tumor growth in an HL-60 acute myeloid leukemia xenograft model[5].
GT19630 (3 mg/kg; i.p.; three times weekly; 2 weeks on/1 week off cycles) induces reversible myelosuppression with minimal body weight loss in humanized CrbnI391V mice, with no observed mortality[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice[4]
-
Dosage:1 mg/kg; 3 mg/kg
-
Administration:i.p.; twice daily
-
Result:Nearly completely eradicated circulating CD20-positive cells.
Ensured 100% survival of mice on day 42 at 3 mg/kg dose, compared with 20% survival in vehicle-treated controls, resulting in significantly prolonged survival.
-
Animal Model:BALB/c nude mice[4]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
-
Administration:i.p.; twice daily (0.1, 0.3, 1 mg/kg); i.p.; once daily (1 mg/kg)
-
Result:Reduced tumor volumes in a dose-dependent manner, with significant suppression across all treatment groups compared to vehicle.
Reduced MYC protein levels in tumors, with the reduction sustained for at least 24-48 hours after a single injection.
-
Animal Model:NOD/SCID mice[4]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:i.p.; twice daily
-
Result:Significantly reduced MM.1S tumor volumes at all dose levels compared to vehicle, even below baseline.
-
Animal Model:BALB/c nude mice (female, 4-6 weeks old)[4]
-
Dosage:3 mg/kg; 6 mg/kg; 12 mg/kg
-
Administration:p.o.; once daily
-
Result:Significantly reduced NCI H526 tumor volumes, with the 12 mg/kg group showing the strongest suppression.
Reduced MYC protein levels in tumors.
-
Animal Model:BALB/c nude mice (female, 4-6 weeks old)[4]
-
Dosage:3 mg/kg; 6 mg/kg; 12 mg/kg
-
Administration:p.o.; once daily
-
Result:Significantly reduced 22RV1 tumor volumes, with the 6 mg/kg and 12 mg/kg groups showing strong suppression.
Reduced MYC protein levels in tumors.
-
Animal Model:NOD/SCID mice[4]
-
Dosage:3 mg/kg
-
Administration:i.p.; once daily
-
Result:Eradicated AML cells in circulation, bone marrow, and spleens.
Resulted in significantly reduced spleen weights compared to vehicle treatment.
-
Animal Model:NSG mice[4]
-
Dosage:3 mg/kg
-
Administration:i.p.; three times weekly; 2 weeks on/1 week off cycles
-
Result:Significantly reduced leukemia burden in both venetoclax-sensitive and venetoclax-resistant groups.
Profoundly reduced AML cells in bone marrow and spleens.
Greatly improved survival: median overall survival was prolonged from 37 days to 119 days in the venetoclax-resistant group, and treated venetoclax-sensitive mice had not reached median survival by study end.
-
Animal Model:C57BL/6 CrbnWT mice; C57BL/6 CrbnI391V (humanized Crbn) mice[4]
-
Dosage:0.3 mg/kg; 3 mg/kg
-
Administration:i.p.; three times weekly; 2 weeks on/1 week off cycles
-
Result:Decreased MYC protein levels in bone marrow cells of CrbnI391V but not CrbnWT mice.
Decreased white blood cell counts in CrbnI391V mice treated with 3 mg/kg, while hemoglobin and platelet levels were unchanged.
Decreased body weights by a maximum of ~5% during treatment, with no deaths or obvious adverse events observed.
Increased murine bone marrow CD45-positive cells significantly post-treatment in CrbnI391V mice, suggesting recovery from myelosuppression.
-
Animal Model:xenograft model[5]
-
Dosage:0.3 mg/kg
-
Administration:twice daily
-
Result:Degraded c-Myc and GSPT1 proteins.
Inhibited tumor growth.
Chemical Information
-
CAS No. 2883535-99-5
-
Appearance Solid
-
Molecular Weight 614.65
-
Formula C35H30N6O5
-
Color White to off-white
-
SMILES
O=C(C1=CC=C2C(N(C3C(NC(CC3)=O)=O)CC2=C1)=O)NCC4=CC=C(CNC(CN5C6=C(C7=CC=CC=C75)C=CC=N6)=O)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (162.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (306 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[2]. Tang M, et al. Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630. Investigational new drugs. 2025 Feb;43(1):167-179. [Content Brief]
[3]. Lin Q, et al. Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025 Dec;12(47):e11789. [Content Brief]
[4].
Nishida Y, et al. Dual MYC and GSPT1 Protein Degrader for MYC-Driven Cancers. bioRxiv. 2025 Apr 27.
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6269 mL | 8.1347 mL | 16.2694 mL | 40.6736 mL |
| 5 mM | 0.3254 mL | 1.6269 mL | 3.2539 mL | 8.1347 mL | |
| 10 mM | 0.1627 mL | 0.8135 mL | 1.6269 mL | 4.0674 mL | |
| 15 mM | 0.1085 mL | 0.5423 mL | 1.0846 mL | 2.7116 mL | |
| 20 mM | 0.0813 mL | 0.4067 mL | 0.8135 mL | 2.0337 mL | |
| 25 mM | 0.0651 mL | 0.3254 mL | 0.6508 mL | 1.6269 mL | |
| 30 mM | 0.0542 mL | 0.2712 mL | 0.5423 mL | 1.3558 mL | |
| 40 mM | 0.0407 mL | 0.2034 mL | 0.4067 mL | 1.0168 mL | |
| 50 mM | 0.0325 mL | 0.1627 mL | 0.3254 mL | 0.8135 mL | |
| 60 mM | 0.0271 mL | 0.1356 mL | 0.2712 mL | 0.6779 mL | |
| 80 mM | 0.0203 mL | 0.1017 mL | 0.2034 mL | 0.5084 mL | |
| 100 mM | 0.0163 mL | 0.0813 mL | 0.1627 mL | 0.4067 mL |